影响firocoxib和tepoxalin治疗犬胃粘膜损伤模型。

文章的细节

引用

复制到剪贴板

古德曼L,托雷斯B,庞克J,雷诺兹L说,埃利斯,Budsberg年代

影响firocoxib和tepoxalin治疗犬胃粘膜损伤模型。

J兽医实习生地中海。2009;1 - 2月23 (1):56 - 62。doi: 10.1111 / j.1939-1676.2008.0226.x。

PubMed ID

19175721 (在PubMed

]

文摘

背景:是知之甚少的影响双环氧合酶(COX)和脂氧合酶抑制对犬胃粘膜愈合。目的:本研究比较公认的双重影响的考克斯和5-lipoxygenase抑制与COX - 2选择性抑制在狗胃粘膜病变愈合。动物:六个研究正常成人的混血狗。必威国际app方法:身体和幽门胃损伤诱导的内镜活检。狗对待tepoxalin、firocoxib或安慰剂在随机7天我家的交叉研究设计。治疗评估天2、4、7内镜治疗的病变得分。类二十烷酸浓度在等离子体和病变的利润率是决定第二天,4和7。重复测量分析。所有的假设测试是双向的P < . 05。多个比较调整使用图基的测试。 RESULTS: Significant treatment differences were noted in the pyloric lesion area measurements. Overall, the firocoxib group had larger lesions than the placebo (P= .0469) or tepoxalin (P= .0089) groups. Despite larger pyloric lesions in the firocoxib group, mucosal prostaglandin production did not differ significantly from placebo. In contrast, the tepoxalin group had significantly lower pyloric mucosal prostaglandin production compared with the firocoxib (P < .0001) or the placebo (P < .0001) groups but pyloric lesions were not significantly larger than those of the placebo group (P= .7829). CONCLUSION: COX-2 inhibition by firocoxib slowed wound healing by a mechanism independent of prostaglandin synthesis. Suppression of mucosal prostaglandin production by tepoxalin did not alter mucosal lesion healing compared with placebo.

DrugBank数据引用了这篇文章

药物

Tepoxalin